484 related articles for article (PubMed ID: 16952494)
1. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
[TBL] [Abstract][Full Text] [Related]
3. Ghrelin improves endothelial function in patients with metabolic syndrome.
Tesauro M; Schinzari F; Iantorno M; Rizza S; Melina D; Lauro D; Cardillo C
Circulation; 2005 Nov; 112(19):2986-92. PubMed ID: 16260640
[TBL] [Abstract][Full Text] [Related]
4. Effect of spironolactone on endothelial dysfunction in rheumatoid arthritis.
Syngle A; Vohra K; Kaur L; Sharma S
Scand J Rheumatol; 2009; 38(1):15-22. PubMed ID: 18766955
[TBL] [Abstract][Full Text] [Related]
5. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
6. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
Tikiz C; Utuk O; Pirildar T; Bayturan O; Bayindir P; Taneli F; Tikiz H; Tuzun C
J Rheumatol; 2005 Nov; 32(11):2095-101. PubMed ID: 16265685
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response.
Marotte H; Maslinski W; Miossec P
Arthritis Res Ther; 2005; 7(1):R149-55. PubMed ID: 15642135
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
[TBL] [Abstract][Full Text] [Related]
10. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy.
Gonzalez-Juanatey C; Llorca J; Vazquez-Rodriguez TR; Diaz-Varela N; Garcia-Quiroga H; Gonzalez-Gay MA
Arthritis Rheum; 2008 Dec; 59(12):1821-4. PubMed ID: 19035415
[TBL] [Abstract][Full Text] [Related]
11. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment.
Foster W; Carruthers D; Lip GY; Blann AD
J Rheumatol; 2010 Apr; 37(4):711-6. PubMed ID: 20156948
[TBL] [Abstract][Full Text] [Related]
12. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity.
Kerekes G; Szekanecz Z; Dér H; Sándor Z; Lakos G; Muszbek L; Csipö I; Sipka S; Seres I; Paragh G; Kappelmayer J; Szomják E; Veres K; Szegedi G; Shoenfeld Y; Soltész P
J Rheumatol; 2008 Mar; 35(3):398-406. PubMed ID: 18203326
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans.
Rask-Madsen C; Domínguez H; Ihlemann N; Hermann T; Køber L; Torp-Pedersen C
Circulation; 2003 Oct; 108(15):1815-21. PubMed ID: 14530204
[TBL] [Abstract][Full Text] [Related]
14. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
[TBL] [Abstract][Full Text] [Related]
15. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Chia S; Qadan M; Newton R; Ludlam CA; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2003 Apr; 23(4):695-701. PubMed ID: 12692009
[TBL] [Abstract][Full Text] [Related]
16. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N; Kawauchi S; Furuya T; Inaba N; Matsuda K; Ando S; Ogasawara M; Aburatani H; Kameda H; Amano K; Abe T; Ito S; Takeuchi T
Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
[TBL] [Abstract][Full Text] [Related]
18. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2.
Lorenz HM; Grünke M; Hieronymus T; Antoni C; Nüsslein H; Schaible TF; Manger B; Kalden JR
J Rheumatol; 2000 Feb; 27(2):304-10. PubMed ID: 10685789
[TBL] [Abstract][Full Text] [Related]
19. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
[TBL] [Abstract][Full Text] [Related]
20. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
